| Original language | English |
|---|---|
| Pages (from-to) | 194-195 |
| Number of pages | 2 |
| Journal | Vaccine |
| Volume | 36 |
| Issue number | 2 |
| DOIs |
|
| Publication status | Published - 4 Jan 2018 |
| Externally published | Yes |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Vaccine, Vol. 36, No. 2, 04.01.2018, p. 194-195.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
TY - JOUR
T1 - Advancing collaborative vaccine benefits and safety research in Europe via the ADVANCE code of conduct
AU - Sturkenboom, Miriam
N1 - Funding Information: The ADVANCE project has received support from the Innovative Medicines Initiative Joint Undertaking ( www.imi.europa.eu ) under Grant Agreement no. 115557 , resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. Funding Information: Public and private stakeholders in Europe recognized that building an integrated and sustainable framework for estimation and monitoring of vaccine effects is of paramount importance in the evaluation of the impact of vaccines in Europe. Any such system will fail to achieve its full potential if built on time-limited project based funding, which unfortunately is still reality in the EU. In this EU reality, where most resources lie at a national level, and ECDC, EMA, European Commission and vaccine manufacturers have supranational interests, it was important to explore whether a public-private collaboration could be established to support public health and regulatory decision-making on vaccine benefit-risk profiles. Vaccine manufacturers launched a call under the 7th call under Innovative Medicines Initiative (IMI)-1, which is funded by the European Commission. The ADVANCE (Accelerated Development of VAccine beNefit-risk Collaboration in Europe) consortium was selected to fulfill the goals of this project call [5–8] ( www.advance-vaccines.eu ) . Among the 27 full partners and the others associate partners are important EU level stakeholders such as the ECDC and EMA, nine national or regional public health institutes, eight national regulatory bodies, seven vaccine manufacturers, and sixteen research institutions across nineteen countries.
PY - 2018/1/4
Y1 - 2018/1/4
UR - http://www.scopus.com/inward/record.url?scp=85033773689&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2017.08.043
DO - 10.1016/j.vaccine.2017.08.043
M3 - Comment/Letter to the editor
AN - SCOPUS:85033773689
SN - 0264-410X
VL - 36
SP - 194
EP - 195
JO - Vaccine
JF - Vaccine
IS - 2
ER -